Pharmacoeconomic analyses in clinical trials. Principles and practice;Inclusión de análisis farmacoeconómicos en ensayos clínicos: Principios y prácticas

Medicina Clinica

Volumn 120, Issue 6, 2003, Pages 227-235

  Álvarez, Javier Soto ^a  

^a Pharmacia SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; NEW DRUG;

CLINICAL PROTOCOL; CLINICAL RESEARCH; COMMERCIAL PHENOMENA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG MARKETING; ECONOMIC EVALUATION; HEALTH ECONOMICS; HUMAN; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRACTICE GUIDELINE; REVIEW; STATISTICAL ANALYSIS;

EID: 0037460438     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13043319     Document Type: Review

References (69)

1. Kessler DA. The regulation of investigational drugs. N Engl J Med 1989;320:281-8.
2. Klimt CR. The conduct and principles of randomized clinical trials. Control Clin Trials 1981;1:283-93.
3. Bakke O, Carné X, García Alonso F. Ensayos clínicos con medicamentos. Fundamentos básicos, metodología y práctica, Barcelona: Doyma, 1994.
4. Brotons Cuixart C. Medicina basada en la evidencia: un reto para el siglo XXI. Med Clin (Barc) 1998;111:552-7.
5. Soto J, Fernández P. Evaluación económica de medicamentos: aplicaciones prácticas para los diferentes agentes decisores. Med Clin (Barc) 1998;110:699-702.
6. Soto J. Utilidad de la incorporación de análisis de evaluación económica en los protocolos de los ensayos clínicos. Med Clin (Barc) 1998; 110:157-8.
7. Osterhaus JT, Townsend RJ. Incorporating pharmacoeconomic research into clinical trials. En: Bootman JL, Townsend RJ, McGhan WF, et al, editors. Principles of pharmacoeconomics. Cincinnati: Harvey Whitney Books, 1996; p. 196-211.
8. Koopmanschap MA. Cost of illness studies. Useful for health policy? PharmacoEconomics 1998;14:143-8.
9. Glick H, Kinosian B, Schulman K. Decision analytic modeling: some uses in the evaluation of new pharmaceuticals. Drug Inf J 1994;28:691-707.
10. Grabowski H. The effect of pharmacoeconomics on company research and development decisions. PharmacoEconomics 1997;11:389-97.
11. Data JL, Willke RJ, Barnes JR, DiRome PJ. Re-engineering drug development: integrating pharmacoeconomic research into the drug development process. Psychopharmacol Bull 1995;31:67-73.
12. Clemens K, Garrison LP, Jones A, Macdonald F. Strategic use of pharmacoeconomic research in early drug development and global pricing. PharmacoEconomics 1993;4:315-22.
13. Schulman KA, Lane T, Yabroff KR. Economic assessment within the clinical development program. Med Care 1996;34:DS89-95.
14. Soto J, Sacristán JA, Galende I. Estudios naturalísticos para valorar la efectividad de los medicamentos tras su comercialización: ¿por qué, cuándo y cómo? Aten Primaria 1998;22:182-5.
15. Bailey KD, Generalizing the results of randomised clinical trials. Control Clin Trials 1994;15:15-23.
16. Drummond M, Jönsson B, Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997; 40:199-215.
17. Johnsson JA, Friesen E. Reassessing the relevance of pharmacoeconomic analyses in formulary decisions. PharmacoEconomics 1998;13: 479-85.
18. Johannesson M. Economic evaluation of drugs and its potential uses in policy making. PharmacoEconomics 1995;8:190-8.
19. Drummond M. Economic, analysis in clinical trials. Br M J Econ 1993; 6(Suppl A):17-8.
20. bloon BS, Fendrick AM. Timing and timeliness in medical care evolution. PharmacoEconomics 1996;9:183-7.
21. Haycox A, Drummond M, Walley T. Pharmacoeconomics: integrating economic evaluation into clinical trials. Br J Clin Pharmacol 1997; 43:559-62.
22. Drummond M. Economic analysis alongside clinical trials: Problems and potential. J Rheumatol 1995;22:1403-7.
23. Davidoff AJ, Powe NR. The role of perspective in defining economic measures for the evaluation of medical technology. Int J Technol Assess Health Care 1996;12:9-21.
24. Copley-Morriman C, Lair T. Valuation of medical resource units collected in health economic studies. Clin Ther 1994;16:553-68.
25. Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984;5:115-8.
26. Wong JM, Mehta SS. Health outcomes gathering in clinical trials, economic and humanistic assessments. Drug Inf J 2001;35:173-9.
27. Donaldson C, Hundley V, McIntosh E. Using economics alongside clinical trials: why we cannot choose the evaluation technique in advance? Health Econ 1996;267-9.
28. Zhon XH, Melfi CA, Hui SL. Methods for comparison of cost data. Ann Intern Med 1997;127:752-6.
29. Coyle D, Davies L, Drummond MF. Emerging issues in designing economic evaluations alongside clinical trials. Int J Techn Assess Health Care 1998;14:135-44.
30. Gray AM, Marshall M, Lockwood A, Morris J. Problems in conducting economic evaluations alongside clinical trials. Lessons from a study of case management for people with mental disorders. Br J Psychiatry 1997;170-47-52.
31. Briggs A. Economic evaluation and clinical trials: size matters. BMJ 2000;321:1362-3.
32. Soto J. Cálculo del tamaño muestral en las evaluaciones económicas de medicamentos. Med Clin (Barc) 1999;112:797.
33. Al MJ, Van Hont BA, Rutten FFH. Sample size calculations in economic evaluations. Health Econ 1998;7:327-35.
34. Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Decis Making 1998;18(Supl):81-92.
35. Brigs AW. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999;8:257-61.
36. O'Hagan A, Stevens JW. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Med Decid Making 2001;21:219-30.
37. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999;48:13-27.
38. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease, PharmacoEconomics 1996;10:460-6.
39. Cohen DJ, Breall JA, Kalon KLH, Ho KK, Weintraub RM, Kintz RE, et al. Economics of elective coronary revascularization: comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol 1993;22:1052-9.
40. Raisch DW. Understanding quality-adjusted life years and their application to pharmacoeconomic research. Ann Pharmacother 2000;34: 906-14.
41. Bennett KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade off and standard gamble technique. En: Spilker B, editors. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven 1996; 253-65.
42. Briggs A, Gray A. The distribution of health care cost and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998;3:233-45.
43. Rutten-van Molken MP, Van Doorslaer EK, Van Vliet RC. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994;3:333-45.
44. Thompson SG, Barber JA. How should cost data in pragmatic randomized trials be analysed? BMJ 2000;320:1197-200.
45. Desgagne A, Castilloux A, Angers J, La Lorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998;13:487-97.
46. Koopmanschap MA, Tuw KCR, Rutten FFH. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001;58:175-86.
47. Briggs AH, O'Brien B. The death of cost-minimization analysis? Health Econ 2001;10:179-84.
48. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 1997;6:243-52.
49. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: and application of Fieller's theorem. Health Econ 1996;5:297-305.
50. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med 1996;15:1447-58.
51. Bala MV, Mauskopf J. The estimation and use of confidence intervals in economic analysis. Drug Inf J 1999;33:841-8.
52. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:243-52.
53. O'Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Stat Med 2001;20:733-53.
54. Lin DY, Fever EJ, Etzioni R, Wax Y. Estimating medical costs for incomplete follow-up data. Biometrics 1997;53:419-34.
55. Bang H, Tsiatis AA. Estimating medical costs for incomplete follow-up data. Biometrics 1997;53:419-34.
56. Briggs A, Schulper M, Buxton M. Uncertainty in the economic evaluation of healthcare technologies: the role of sensitivity analysis. Health Econ 1994;9:95-104.
57. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18(Suppl):68-80.
58. Craig BA, Black MA. Incremental cost-effectiveness ratio and incremental met-health benefit: two sides of the same coin. Expert Rev Pharmacoeconomics Outcomes Res 2001;1:37-46.
59. Hornberger J. Introduction to Bayesian reasoning. Int J Technol Assess Health Care 2001;17:916.
60. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ 1998;7:481-93.
61. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000;17:339-49.
62. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7:481-93.
63. Pang F. Design, analysis and presentation of multinational economics studies. The need for a guidance. Pharmacoeconomics 2002;20:75-90.
64. O'Brien B. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Med Care 1996;34:DS99-108.
65. Ellwein LB, Drummond MF. Economic analysis alongside clinical trials. Int J Tech Assess Health Care 1996;12:691-7.
66. Baker AM, Arnold RJG, Kaniecki DJ. Economic analysis in clinical trials: practical considerations. Drug Inf J 1999;33:1053-60.
67. Soto J. Farmacoeconomia como instrumento de ayuda en la toma de decisión: presente y futuro en nuestro país. Rev Esp Farmacoeconomía 1998;4:19-21.
68. Healy M, Deverka P. Panel I: methodological issues in pharmacoeconomic evaluations-Clinical studies. Value Health 1999;2:73-7.
69. Bentkover JD, Corey R. Effective utilization of pharmacoeconomics for decision makers. Dis Manage Health Outcomes 2002;10:75-80.